49 results on '"Younes, Ziad H"'
Search Results
2. LBP-040 Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): interimresults for 2 years from the ASSURE study
3. LBO-006 A prospective, blinded, multicenter U.S. evaluation of a multianalyte blood-based test for the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis
4. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.
5. Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitis.
6. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders
7. S954 Experiences With Bowel Preparation for Colonoscopy in Crohn’s Disease
8. The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH
9. 653: PATIENTS WITH INFLAMMATORY BOWEL DISEASE HAVE IMPAIRED HUMORAL BUT PRESERVED CELLULAR RESPONSES TO SARS-COV-2 MRNA VACCINATION
10. 656: POST-VACCINATION SYMPTOMS AFTER A THIRD DOSE OF SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
11. OS-019 Efficacy and safety of seladelpar in patients with primary biliary cholangitis and compensated liver cirrhosis in the open-label, long-term ASSURE safety study: interim results
12. Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
13. LIVRQNac (AXA1125) ENHANCES INSULIN SENSITIVITY IN PRIMARY HUMAN HEPATOCYTES AND IN SUBJECTS WITH NAFLD AND T2D
14. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
15. Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease
16. Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
17. Fr544 EVALUATING THE COST SAVINGS OF A MULTICENTER QUALITY IMPROVEMENT PROGRAM FOR IMPROVING THE DELIVERY OF IBD URGENT CARE
18. Long-term safety profile of cenicriviroc in adults with non-alcoholic steatohepatitis: rollover study
19. The clinical and patient reported outcomes (PROs) profile of patients with non-alcoholic fatty liver disease (NAFLD) from real-world practices varies across the world
20. Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D)
21. Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis
22. Sa1759 IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE CARE DOES NOT DIFFER BY PRACTICE TYPE
23. Tu1673 LONG-TERM SAFETY PROFILE OF CENICRIVIROC IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS: ROLLOVER STUDY
24. Sa1757 THE IBD URGENT CARE TOOLKIT: WHICH PROCESS CHANGES ARE ASSOCIATED WITH SUCCESSFUL IMPROVEMENT?
25. 23 QUALITY OF CARE INITIATIVE IMPROVES OUTCOMES FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE
26. 329 THE IMPACT OF FATIGUE ON PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (GLR)
27. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
28. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
29. SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis
30. LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension
31. A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s Disease
32. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease
33. 290 - Long-Term Follow-Up of Patients with Chronic HCV Infection and Compensated or Decompensated Cirrhosis Following Treatment with Sofosbuvir-Based Regimens
34. Su1522 - Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK-1) Inhibitor (Selonsertib) in Combination with an Acetyl-Coa Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) in NASH
35. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
36. 604 Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir Treatment of Patients With HCV Genotype 1-Infection Who Failed a Prior Course of DAA Therapy: The QUARTZ-I Study
37. Su1413 Sof/VEL for 12 Weeks Results in High SVR 12 Rates in Subjects With Negative Predictors of Response to Treatment: An Integrated Analysis of Efficacy Fron the ASTRAL-1, ASTRAL-2 and ASTRAL-3 Studies
38. 1016 All-Oral 12-Week Combination Treatment With Daclatasvir (DCV) and Sofosbuvir (SOF) in Treatment-Experienced Patients Infected With HCV Genotype (GT) 3: A Subanalysis of the Ally-3 Phase 3 Study
39. Su1061 Pearl-IV: a 12-Week Regimen of ABT-450/r/ABT-267 and ABT-333, With or Without Ribavirin Achieves Svr12 Rates≥90% in Treatment-Naïve Adults Infected With Hepatitis C Virus Genotype 1A
40. 821Daclatasvir and Asunaprevir Plus Peginterferon Alfa-2a and Ribavirin in Patients With HCV Genotype 1 or 4 Infection: Phase 3 HALLMARK-QUAD Results
41. Su2084 Efficacy of Certolizumab Pegol Induction and Maintenance Therapy in Patients With Crohn's Disease Not in Remission Following Active or Placebo Induction
42. Maintenance Therapy With Certolizumab Pegol After Induction Therapy for Active Crohn's Disease: 6-Month Results
43. Role of growth factors in oesophageal mucosal healing: A work in progress
44. THE IMPACT OF FATIGUE ON PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (GLR)
45. FRI118 - Long-term safety profile of cenicriviroc in adults with non-alcoholic steatohepatitis: rollover study.
46. LBO01 - Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis.
47. FRI452 - Non-invasive tests of fibrosis and risk of liver-related complications: observations following successful sofosbuvir-based treatment in patients with HCV cirrhosis.
48. LBP01 - Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D)
49. AS162 - The clinical and patient reported outcomes (PROs) profile of patients with non-alcoholic fatty liver disease (NAFLD) from real-world practices varies across the world.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.